Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients.

Details

Ressource 1Download: 31170218_BIB_B58EBE032B57.pdf (1434.34 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_B58EBE032B57
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients.
Journal
PloS one
Author(s)
Gastaldi G., Gomes D., Schneiter P., Montet X., Tappy L., Clément S., Negro F.
ISSN
1932-6203 (Electronic)
ISSN-L
1932-6203
Publication state
Published
Issued date
2019
Peer-reviewed
Oui
Volume
14
Number
6
Pages
e0217751
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Abstract
Hepatitis C virus (HCV) infection is associated with insulin resistance, which may lead to type 2 diabetes and its complications. Although HCV infects mainly hepatocytes, it may impair insulin sensitivity at the level of uninfected extrahepatic tissues (muscles and adipose tissue). The aim of this study was to assess whether an interferon-free, antiviral therapy may improve HCV-associated hepatic vs. peripheral insulin sensitivity.
In a single-arm exploratory trial, 17 non-diabetic, lean chronic hepatitis C patients without significant fibrosis were enrolled, and 12 completed the study. Patients were treated with a combination of sofosbuvir/ledipasvir and ribavirin for 12 weeks, and were submitted to a 2-step euglycemic hyperinsulinemic clamp with tracers, together with indirect calorimetry measurement, to measure insulin sensitivity before and after 6 weeks of antivirals. A panel of 27 metabolically active cytokines was analyzed at baseline and after therapy-induced viral suppression.
Clamp analysis performed in 12 patients who achieved complete viral suppression after 6 weeks of therapy showed a significant improvement of the peripheral insulin sensitivity (13.1% [4.6-36.7], p = 0.003), whereas no difference was observed neither in the endogenous glucose production, in lipolysis suppression nor in substrate oxidation. A distinct subset of hepatokines, potentially involved in liver-to-periphery crosstalk, was modified by the antiviral therapy.
Pharmacological inhibition of HCV improves peripheral (but not hepatic) insulin sensitivity in non-diabetic, lean individuals with chronic hepatitis C without significant fibrosis.
Keywords
Adult, Antiviral Agents/therapeutic use, Cytokines/blood, Diabetes Mellitus/pathology, Female, Glucose/metabolism, Hepatitis C, Chronic/blood, Hepatitis C, Chronic/drug therapy, Humans, Insulin Resistance, Male, Middle Aged, Thinness/complications, Young Adult
Pubmed
Web of science
Open Access
Yes
Create date
24/06/2019 8:16
Last modification date
30/04/2021 6:14
Usage data